European Commission Grants Marketing Authorization for Gileadâs HarvoniÂ®â¼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4